Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$54.5M Hold
19,822,436
1.74% 20
2025
Q4
$62.2M Hold
19,822,436
2.1% 16
2025
Q3
$57.3M Hold
19,822,436
2.32% 16
2025
Q2
$40.2M Hold
19,822,436
1.44% 15
2025
Q1
$37.1M Buy
19,822,436
+300,000
+2% +$756K 1.51% 13
2024
Q4
$52.7M Hold
19,522,436
1.79% 13
2024
Q3
$73.8M Buy
19,522,436
+687,500
+4% +$2.4M 2.16% 13
2024
Q2
$75.2M Buy
18,834,936
+4,263,700
+29% +$14.1M 2.11% 17
2024
Q1
$43.1M Hold
14,571,236
1.19% 25
2023
Q4
$72.9M Buy
14,571,236
+7,142,857
+96% +$23M 1.82% 14
2023
Q3
$21.2M Hold
7,428,379
0.57% 34
2023
Q2
$22M Hold
7,428,379
0.61% 33
2023
Q1
$17.4M Hold
7,428,379
0.64% 43
2022
Q4
$15.2M Hold
7,428,379
0.64% 43
2022
Q3
$23.5M Hold
7,428,379
0.97% 34
2022
Q2
$26.8M Hold
7,428,379
1.3% 26
2022
Q1
$29.7M Buy
7,428,379
+366,000
+5% +$1.58M 1.19% 27
2021
Q4
$35M Buy
7,062,379
+127,200
+2% +$739K 1.27% 26
2021
Q3
$46.5M Sell
6,935,179
-1,610,000
-19% -$11.5M 1.82% 17
2021
Q2
$67.8M Buy
8,545,179
+1,040,600
+14% +$7.19M 2.54% 13
2021
Q1
$57.1M Sell
7,504,579
-2,312,079
-24% -$16.5M 2.14% 15
2020
Q4
$50.8M Sell
9,816,658
-2,100
-0% -$10.7K 2% 15
2020
Q3
$47.9M Sell
9,818,758
-1,500,000
-13% -$10.8M 2.61% 10
2020
Q2
$76.2M Sell
11,318,758
-23,747
-0.2% -$173K 4.7% 7
2020
Q1
$78.4M Hold
11,342,505
7.31% 3
2019
Q4
$96.6M Buy
11,342,505
+44,594
+0.4% +$297K 7.33% 3
2019
Q3
$55.9M Buy
11,297,911
+1,478,477
+15% +$7.92M 5.88% 4
2019
Q2
$54.5M Buy
9,819,434
+2,363,900
+32% +$12M 5.95% 4
2019
Q1
$37.6M Buy
7,455,534
+5,225,507
+234% +$33.2M 4.22% 6
2018
Q4
$21.1M Buy
2,230,027
+212,527
+11% +$2.01M 2.75% 12
2018
Q3
$16.1M Buy
+2,017,500
New +$20.3M 1.42% 23

Other funds holding ACIU

BVF Inc's ACIU Position: Q1 2026 in Review

BVF Inc held its AC Immune (ACIU) position steady in Q1 2026 at 19,822,436 shares worth $54.5M. The position accounts for 1.74% of the portfolio, ranked #20.

BVF Inc first reported a position in ACIU in Q3 2018 and has held it in 31 quarters since. The position peaked at $96.6M in Q4 2019. 46 funds tracked by Wall St. Rank hold ACIU as of Q1 2026.

  • BVF Inc held 19,822,436 shares of AC Immune worth $54.5M as of Q1 2026.
  • BVF Inc left its AC Immune share count unchanged in Q1 2026.
  • AC Immune made up 1.74% of BVF Inc's portfolio in Q1 2026, its #20 holding.
  • BVF Inc first reported a position in AC Immune in Q3 2018 and has held it in 31 quarters since.
  • BVF Inc's AC Immune position peaked at $96.6M in Q4 2019.
  • 46 funds tracked by Wall St. Rank held AC Immune as of Q1 2026.

Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.